(0.32%) 5 116.18 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.41%) $2.03
(0.36%) $2 355.60
(0.52%) $27.68
(4.25%) $961.30
(-0.27%) $0.932
(-0.45%) $10.97
(-0.58%) $0.796
(1.63%) $93.37
@ $15.77
発行日: 15 2月 2024 @ 04:20
リターン: -2.42%
前回のシグナル: 2月 14 - 05:31
前回のシグナル:
リターン: 6.45 %
Live Chart Being Loaded With Signals
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States...
Stats | |
---|---|
本日の出来高 | 57 812.00 |
平均出来高 | 389 040 |
時価総額 | 673.64M |
EPS | $0 ( 2024-02-29 ) |
次の収益日 | ( $-0.120 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -31.40 |
ATR14 | $0.0330 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Tagliaferri Mary | Buy | 27 900 | Stock Option (right to buy) |
2024-03-12 | Tagliaferri Mary | Buy | 4 660 | Common Stock |
2024-02-29 | Tagliaferri Mary | Buy | 0 | |
2024-03-05 | Rajah Vignesh | Sell | 1 711 | Common Stock |
2024-03-05 | Gad Thomas | Sell | 3 900 | Common Stock |
INSIDER POWER |
---|
77.63 |
Last 98 transactions |
Buy: 3 651 211 | Sell: 357 293 |
ボリューム 相関
Y-mAbs Therapeutics, Inc 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Y-mAbs Therapeutics, Inc 相関 - 通貨/商品
Y-mAbs Therapeutics, Inc 財務諸表
Annual | 2023 |
収益: | $84.82M |
総利益: | $73.40M (86.54 %) |
EPS: | $-0.490 |
FY | 2023 |
収益: | $84.82M |
総利益: | $73.40M (86.54 %) |
EPS: | $-0.490 |
FY | 2022 |
収益: | $65.27M |
総利益: | $57.70M (88.41 %) |
EPS: | $-2.20 |
FY | 2021 |
収益: | $34.90M |
総利益: | $32.38M (92.80 %) |
EPS: | $-1.378 |
Financial Reports:
No articles found.
Y-mAbs Therapeutics, Inc
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。